Skip to content
value.today

Esperion Therapeutics, Inc.

Total raised
$45 M
2 rounds on record
Latest round
$17 M
Apr 2013
First round on record
Apr 2008
Today
Private
See the company page

Esperion Therapeutics, Inc. is listed today as Esperion Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Esperion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2013$17 MNo. 2$10 to $50 million

Esperion Therapeutics, Inc.: Raise no. 2, Apr 2013

Investors in this round

10 investors had bought by the notice of Apr 26, 2013: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Esperion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Noah L. Rosenberg · Executive Officer
  • Roger S. Newton · Executive Officer, Director
  • Tim M. Mayleben · Executive Officer, Director
  • Troy A. Ignelzi · Executive Officer
  • Daniel A. Janney · Director
  • Dov A. Goldstein · Director
  • Louis G. Lange · Director
  • Nicole G. Vitullo · Director
  • Patrick G. Enright · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tim M. Mayleben, President and CEO. Newest notice filed Apr 26, 2013. Read the notice at the SEC.

equitySEC
Apr 2008$28 MNo. 1$10 to $50 million

Esperion Therapeutics, Inc.: Raise no. 1, Apr 2008

Investors in this round

9 investors had bought by the notice of Feb 11, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Esperion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $39 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Roger S. Newton · Executive Officer, Director
  • Alison S. Kiley · Director
  • Dov S. Goldstein · Director
  • Louis M. Lange · Director
  • Nicole S. Vitullo · Director
  • Timothy M. Mayleben · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Roger S. Newton, President & Chief Executive Officer. Newest notice filed Feb 11, 2011 (1 amendment). Read the notice at the SEC.

equity, debtSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Esperion Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration Revenue $243.60 million (60%), Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received $148.80 million (37%).

    Annual report (SEC XBRL) · Dec 2025

  • Esperion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2013).

    SEC Form D · Apr 2013

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Apr 2013

Products and services#

No products or services of Esperion Therapeutics, Inc. are on record.

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Esperion Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Aisling Capital II LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Aisling Capital Partners LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Aisling Capital Partners, LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Domain Parters VII L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
DP VII Associates LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Longitude Capital Associates, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Longitude Capital Partners, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Longitude Venture Partners L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Louis G. LangePersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2013)SEC Form 3
Roger S. NewtonPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2013)SEC Form 3

Largest shareholders today

Institutions holding Esperion Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Esperion Therapeutics, Inc.
NameRoleNamed in
Noah L. RosenbergExecutive officerApr 2013
Roger S. NewtonExecutive officerApr 2013
Tim M. MaylebenExecutive officerApr 2013
Troy A. IgnelziExecutive officerApr 2013
Daniel A. JanneyDirectorApr 2013
Dov A. GoldsteinDirectorApr 2013
Louis G. LangeDirectorApr 2013
Nicole G. VitulloDirectorApr 2013
Patrick G. EnrightDirectorApr 2013
Roger S. NewtonDirectorApr 2013
Tim M. MaylebenDirectorApr 2013
Alison S. KileyDirectorFeb 2011
Dov S. GoldsteinDirectorFeb 2011
Louis M. LangeDirectorFeb 2011
Nicole S. VitulloDirectorFeb 2011
Timothy M. MaylebenDirectorFeb 2011
Alison S. de BordDirectorFeb 2010

About

American pharmaceutical company.